3651 results for «518»
3651 results
AI adoption in the cathlab of tomorrow - Risk prediction applications
20 May 2026 – From EuroPCR 2026
This session delves into the adoption of artificial intelligence in the cath lab, focusing on clinically useful risk prediction models for coronary and structural interventions. It covers advanced AI-guided intravascular imaging, machine learning applications for adverse event prediction, and critical evaluation of model validation and clinical...
Complex endovascular and pulmonary interventions
20 May 2026 – From EuroPCR 2026
Explore advances in complex endovascular and pulmonary interventions, including the transformation of interventional labs into intelligent learning ecosystems, innovative approaches to peripheral and coronary CTOs, and novel therapies such as extravascular renal denervation and fixation catheters for acute pulmonary embolism.
Beyond first implant: valve-in-valve, redo and leaflet modification
20 May 2026 – From EuroPCR 2026
This session explores advanced transcatheter aortic valve therapies beyond the first implant, focusing on valve-in-valve, redo procedures, and leaflet modification techniques. Topics include bioprosthetic valve fracture, long-term outcomes from the DURA-ViV registry, simplified workflows for leaflet modification in redo-TAVI, and intravascular ultrasound evaluation of valve expansion...
TAV-in-SAV TAVI procedure - LIVE case
21 May 2026 – From EuroPCR 2026
A 70‑year‑old man with COPD and a history of severe aortic stenosis treated with SAVR (27 mm Perimount Magna) in 2012, followed by endocarditis in 2013, presented with symptomatic degeneration of the surgical valve, predominantly as severe aortic regurgitation. Left ventricular function was preserved (LVEF 50%)...
Adopting a step-by-step approach for successful redo TAVI
21 May 2026 – From EuroPCR 2026
This session outlines a systematic step-by-step approach for redo TAVI procedures, including detailed pre-procedural CT analysis. It addresses challenges associated with failing short and tall-frame valves, and discusses coronary protection and leaflet modification techniques critical for successful reinterventions.
Routine primary PCI: what can go wrong?
21 May 2026 – From EuroPCR 2026
This session offers an in-depth examination of potential complications during routine primary PCI, focusing on prevention and management strategies. Key learning points include understanding no-reflow phenomena, managing STEMI in post-CABG patients, and handling thrombus burden effectively. Real-world cases illustrate decision-making processes and therapeutic approaches to optimize...
Insight from recent evidence in coronary artery disease: value of DCB for de novo lesions (SELUTION) and imaging for left main PCI (OPTIMAL)
21 May 2026 – From EuroPCR 2026
This session reviews pivotal recent evidence impacting daily practice in coronary artery disease management. It discusses the role of drug-coated balloons (DCB) for de novo lesions as evaluated in the SELUTION trial and evaluates intracoronary imaging strategies for left main PCI as presented in the OPTIMAL...
The structural bailout playbook: managing complications
21 May 2026 – From EuroPCR 2026
The session presents a practical structural bailout playbook focused on managing complex complications during structural heart interventions. It features challenging cases such as unusual atrial septal defect closure complications, navigation of a displaced patent ductus arteriosus stent in infants, percutaneous closure of mitral paravalvular leaks with...
CTO ADVANCED Level I: LIVE Educational Cases from Institut Cardiovasculaire Paris Sud, France & University Hospital Basel, Switzerland
21 May 2026 – From EuroPCR 2026
This advanced level I CTO session features live educational cases from Institut Cardiovasculaire Paris Sud and University Hospital Basel, focusing on structured procedure analysis, imaging-based planning, and integrated CTO techniques. Detailed case presentations and live procedural demonstrations underscore strategies for success in complex CTO interventions.
Revascularisation in patients with multivessel disease and severe left ventricular impairment
21 May 2026 – From EuroPCR 2026
This session focuses on revascularisation strategies for patients with multivessel coronary disease complicated by severe left ventricular impairment. It emphasizes patient selection criteria, the crucial role of the heart team in decision-making, and optimization of percutaneous revascularisation outcomes. The content includes comprehensive case presentations and discussions...
The impact of calcified and resistant lesions in clinical outcome of PCI
21 May 2026 – From EuroPCR 2026
Delve into the clinical implications of calcified and resistant coronary lesions on percutaneous coronary intervention (PCI) outcomes. This session presents key registry data and study results on intravascular lithotripsy and plaque modification techniques, highlighting their impact on patient prognosis and stent performance.
Advanced heart failure: left ventricular assist device as bridge to optimise guided-directed medical therapy
21 May 2026 – From EuroPCR 2026
This session explores advanced heart failure management with a focus on guided-directed medical therapy and the role of left ventricular assist devices (LVAD) as a bridge to therapy optimization. It discusses clinical, imaging, and biological parameters indicating LVAD use and highlights devices such as the Impella...
Physiological vs. anatomical assessment of multivessel disease patients
21 May 2026 – From EuroPCR 2026
This session delves into the comparative benefits of physiological versus anatomical assessment in patients with multivessel coronary disease, focusing particularly on myocardial infarction cases. Attendees will explore how coronary physiology can guide complete revascularisation, the added value of physiological assessment beyond conventional angiography, and the selection...
Optimising the results of non-left main bifurcation PCI
21 May 2026 – From EuroPCR 2026
This session focuses on optimizing outcomes in non-left main bifurcation PCI by emphasizing lesion preparation and stent sizing guided by intravascular imaging. It integrates physiological and imaging assessments for confident final result evaluation and discusses criteria for selecting upfront two-stent strategies in bifurcation lesions.
Advancing TAVI practice
21 May 2026 – From EuroPCR 2026
Advancing TAVI practice is the focus of this session, addressing antiplatelet therapy choices, novel transcatheter treatments for pure aortic regurgitation, early hemodynamic valve deterioration as a prognostic marker, prosthesis-patient mismatch in redo-TAVI, pioneering valve-in-mechanical valve interventions, and comprehensive core-lab evaluation of implantation depth and clinical outcomes.
TAVI procedural complications - Part 7: coronary protection, valve embolisation, and more
21 May 2026 – From EuroPCR 2026
This session addresses complex procedural complications in TAVI, featuring challenging cases such as rupture of the sinus of Valsalva, innovative bailouts for valve embolisation, mechanisms of aorta-right ventricular fistula post-TAVI, and management strategies for failed surgical aortic valves after endocarditis.
TAVI - Procedural strategy
21 May 2026 – From EuroPCR 2026
This session focuses on procedural strategies for TAVI, examining the influence of coronary artery disease severity on PCI decision-making, revascularisation approaches in high-bleeding risk patients, the role of CT imaging and implant depth in procedural planning, and comparative evaluation of pre-dilatation versus direct valve implantation in...
Is DCB the new gold standard for side branch treatment in bifurcation?
21 May 2026 – From EuroPCR 2026
This session explores the emerging role of drug-coated balloons (DCB) as a potential new standard for side branch treatment in bifurcation lesions. It focuses on selecting appropriate indications, optimal vessel preparation and delivery timing, and executing stepwise DCB strategies versus hybrid approaches to maximize clinical outcomes.
Beyond the diagnosis: a qualitative exploration of women’s experiences with cardiovascular disease
21 May 2026 – From EuroPCR 2026
This session presents a qualitative exploration of women's experiences with cardiovascular disease, highlighting unique challenges throughout their care pathway from diagnosis to rehabilitation. It shares robust patient experience data and offers recommendations aimed at improving cardiovascular care tailored to women’s specific needs.
TAVI complications - Prediction, reduction, avoidance
21 May 2026 – From EuroPCR 2026
This session examines prediction, reduction, and avoidance of complications associated with TAVI procedures. It covers outcomes of second-valve implantation as a bail-out for valve migration, predictors of permanent pacemaker implantation post-TAVI from the LANDMARK trial, neurological event prognostics based on timing, and management of periprocedural cardiac...
